secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0000950170-24-015230
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M
-------------------------------------------------------------------------

- Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.
- clonoSEQ test volume up 53% YoY to 56,496 tests delivered in 2023.
- Net loss $225.3M in 2023 vs $200.4M in 2022; includes $25.4M lease impairment charge.
- Adjusted EBITDA loss $116.4M in 2023 vs $121.6M loss in 2022.
- 2024 MRD revenue guidance $130-140M; total OpEx guided to $360-370M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/adpt-20240214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-015230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer